Disaggregated Revenues

9 Months Ended

Sep. 30, 2022

Disaggregation of Revenue [Abstract]

Disaggregated Revenues

Disaggregated Revenues

The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
	(unaudited)				(unaudited)
Net product sales
Trokendi XR	$	69,599	$	80,935	$	204,033	$	231,531
Oxtellar XR	30,528		29,728		88,007		82,120
GOCOVRI	27,878		—		75,179		—
Qelbree	18,326		2,370		37,708		2,685
APOKYN	$	18,261	$	24,627	$	57,156	$	73,338
Other(1)	8,132		7,872		23,564		22,867
Total net product sales	$	172,724	$	145,532	$	485,647	$	412,541
Royalty revenues	4,629		2,932		14,263		8,184
Total revenues	$	177,353	$	148,464	$	499,910	$	420,725

______________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Trokendi XR accounted for more than 40% of the Company’s total net product sales for both the three and nine months ended September 30, 2022, and 56% of the Company's total net product sales for both the three and nine months ended September 30, 2021, respectively.

Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 25% of our total net product sales for both the nine months ended September 30, 2022 and 2021, and collectively accounted for more than 80% and 85% of our total net product sales for the nine months ended September 30, 2022 and 2021, respectively.

Royalty revenues include noncash royalty revenues. The Company recognized noncash royalty revenue of $2.5 million and $7.2 million, for the three and nine months ended September 30, 2022, respectively. The Company recognized noncash royalty revenue of $2.4 million and $6.8 million, for the three and nine months ended September 30, 2021, respectively. Refer to Note 16, Commitments and Contingencies.